231 results about "Dry Eye Syndromes" patented technology

A treatment for dry eye syndrome. An at least partially sealed chamber including a reservoir for moisture for surrounding the eyes is disclosed. The invention may be transparent for use during the day or in association with prescription or non-prescription lenses. The moisture chamber may also be opaque to act as a blackout mask for sleeping.

Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.

The invention relates to a method of insulin eye drops for treating dry eye syndrome due to any and all etiological factors (Keratoconjunctivitis sicca), including Sjogren's syndrome, Meibomian gland dysfunction (MGD) and other glandular malfunction in the eye lids, lacrimal glands, cornea, conjunctiva, and exposed scleral surface of the eye. It is treated with Insulin and/or IGF-I with or without known anti-dry eye syndrome therapeutic, pharmaceutical, biochemical and biological agents or compounds.

Provided herein are methods of evaluating efficacy of a treatment in a subject having eye inflammation (e.g., a subject having dry eye syndrome) and selecting a subject for participation in a clinical study. Also provided are methods of treating a subject having eye inflammation (e.g., a subject having dry eye syndrome).

Provided are methods and systems for treating or preventing dry eye syndrome in a subject. The methods involve applying light of a set of photomodulating parameters to the region of the eyelid. The light of these particular photomodulating parameters will increase the production of collagen, elastin or both thereby improving the tone of the eyelid. Improved eyelid tone will increase the level of meibum secreted through the meibomian duct thereby treating or preventing dry eye syndrome. Particular apparatuses are provided that emit and locate light of the necessary photomodulating parameters tailored for delivery to the eyelid areas activating fibroblasts specifically in this area and thereby improving eyelid tone and meibomian gland function.

The invention discloses an eye medicine combination, containing 200-400 parts by weight of lutein, 1-2 parts by weight of DHA, 6-7 parts by weight of vitamin A and 1.5-2.5 parts by weight of selenium. The components of the eye medicine combination provided by the invention have synergic effect, thus being capable of alleviating symptoms such as asthenopia and dry eye syndrome and being capable of racially controlling and preventing eye problems such as cataract, glaucoma, floaters, macular pigment cytopathy and the like as well, thereby improving eyesight.

Eye degradation such as may be associated with dry eye syndrome is inhibited or reversed by administration of an actin-sequestering peptide such as Thymosin beta4, an isoform of Tymosin beta4 or oxidized Thymosin beta4.

The invention discloses blue light resistant dark down sunglasses lenses, made by mixing polycarbonate PC, 7308 toner, 8416 toner, 8415B toner and 8410 toner; wherein every 100kg of polycarbonate PC is added with 6.13g of 7308 toner, 5.56g of 8416 toner, 7.97g of 8415B toner and 0.94g of 8410 toner. The sunglasses lenses are in dark brown, can effectively prevent light with the wavelength of 380-500nm from passing through, reduces harm of blue light to eyes, protects the eyes, prevents eye disease such as cataract and is especially applicable to person received cataract surgery, person with macular degradation family history, person in maintenance period after laser surgery, students who are suffering pseudomyopia and want to control myopic degree not to be increased, person who enjoys outdoor activity or works outdoor, person who lives in hot climate and sunny area, person taking medicine with photosensitivity, person who uses computer for a long time and person suffering from dry eye syndrome.

The present invention relates to oxygenated ophthalmic topical compositions and methods of administering oxygenated ophthalmic topical compositions. The present invention also encompasses methods for making and administering the oxygenated ophthalmic topical compositions for use in treating or ameliorating pathologic conditions, complications, diseases and symptoms related to hypoxia of the anterior eye structure, including corneal neovascularization (CNV), edema, abrasions, infections, infiltrates, dry eye syndrome, contact lens intolerance; and redness, blurred vision, discomfort, foreign body sensation, photophobia, and irritation.

The present invention discloses a tear analyzing strip (TAS) for measuring dry eye syndrome in a patient. The TAS comprises an elongated body comprising a proximal portion and a distal portion interconnected by a main longitudinal axis. The distal portion comprises at least one tear channel comprising at least one tear receiving portion in fluid communication with an eye of the patient such that tears sampled from the eye into the channel. Reagent pads disposed along the length of the distal portion. The reagent pad is in fluid communication with the tear channel such that tears flow through the tear channel towards the reagent pads, thereby progressively wetting the reagent pads. Each of the reagent pads comprises an effective measure of a reagent capable of biological, physical, or chemical activation by the tears or a component thereof and of providing a visible indication of the activation.

Eye degradation such as may be associated with dry eye syndrome is inhibited or reversed by administration of an actin-sequestering peptide such as Thymosin β4, an isoform of Thymosin β4 or oxidized Thymosin β4.

The invention relates to a point eye mask and a preparation and application thereof, the point eye mask comprises a back lining layer, a drug storage layer and a protective layer, wherein, the drug storage layer is formed by coating the drug emulsion containing PSA (pressure sensitive adhesive), skin transdermal enhancer and other drugs onto the back lining layer, wherein, the drug emulsion is formed by blending nano-powder of Chinese herbal extract for szechwan lovage rhizome, radix salviae miltiorrhizae, angelica sinensis, chrysanthemum, plantago asiatica, semen celosiae, cuscuta chinensis lam, equisetum hiemale linne, fructus ligustri lucidi, radix glycyrrhiza, and cassia seed and the like; a polyester film protective layer is covered onto the back lining layer, and the eye mask is formed through cutting. The point eye mask adopts principles of traditional Chinese acupuncture and release and control technology of modern transdermal, can constantly release active ingredients in points for a long period of time, can well adjust and improve muscles, nerves, and blood vessels at and around the eyes, can play a certain role in delaying for development of myopia of young people, and play a role in treatment for fatigue blurred vision, high intraocular pressure, presbyopia, and dry eye syndrome. Meanwhile, the invention has advantages of convenient using, persistent efficacy.

The present invention refers to pharmaceutical formulations based on lipids for ophthalmic use comprising a phospholipid component composed of zwitterionic phospholipids of natural origin and an oily component composed of oils of natural origin emulsified in water. In particular, the invention refers to ophthalmic formulations useful, for example, for transporting drugs to the eye and in the treatment of ocular dryness, capable of restoring the lipid layer of the tear film. In particular, in a non-transitory but pathological situation such as the dry eye syndrome, such formulations also succeed in reducing the often-present inflammatory component.

Disclosed is a mucoadhesive nanoparticle delivery system for delivering an immunosuppressant, such as cyclosporine A, to a mucosal site for treatment of a disease or condition involving inflammation or excess immune activity. The system comprises nanoparticles formed from a plurality of linear amphiphilic block copolymers, each having a hydrophobic block comprising polylactide (PLA) and a hydrophilic block comprising dextran. The nanoparticles are surface-functionalized with a mucosal targeting moiety, such as a phenylboronic acid derivative, for targeted delivery and enhanced retention at the mucosal site. Pharmaceutical compositions, methods, and uses thereof comprising the mucoadhesive nanoparticle delivery system are disclosed. The compositions can be administered in an effective amount for treating the disease or condition while substantially preserving or restoring the function and/or integrity of the mucosal lining. The composition may be formulated as an aqueous suspension for administration to an anterior surface of the eye in the treatment of dry eye syndrome.

A pharmaceutically acceptable carrier for ophthalmic compositions useful in treating or alleviating the symptoms of dry eye syndrome, elevated intra-ocular pressure, age-related maculopathy or age-related macular degeneration.

Warm compresses are the most widely prescribed effective medical therapy for several common eye conditions namely dry eye syndrome, blepharitis and chalazia. These problems are caused by blockage of natural oil flow through pores located behind the eyelashes (meibomian glands). Warm compresses open these pores and restores normal flow of natural oils to the eye surface; these oils moisturize the eye by preventing evaporation of tears from the eye surface. The novel aspects of this invention that make it unique include the ability to generate long lasting, self-perpetuating moist heat, with hands free convenience. By allowing patients to continue to work, play, read or watch television while receiving the therapeutic benefits of a moist warm compress this invention is highly likely to increase compliance and improve quality of life for millions of patients with these common and highly troublesome eye conditions.

The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosuppressants. They can be administered topically into the eye. The invention further provides kits comprising such compositions.

A composition and method for treating dry-eye syndrome and symptoms of vitreous opacities in a host comprising the oral administration of a composition which contains a pharmacologically effective amount of essential fatty acids, polar phospholipids, vitamins, minerals and dietary supplements.

Improved indices for the diagnosis and evaluation of conditions affecting the eye. Specifically, the indices include an Enhanced Epithelial Irregularity Factor (eEIF) for the diagnosis and evaluation of conditions such as dry eye syndrome (DES), Bowman's Ectasia Index (BEI), including enhanced BEI (eBEI) and BEI-Max, and Bowman's Relative Thinning (BRT) Index for the diagnosis and evaluation of ectatic conditions such as keratoconus, pellucid marginal degeneration, post-refractive surgery ectasia, and keratoglobus, and Descemet's Membrane Thickening Index (DMT), Descemet's Rejection Index (DRI), and Descemet's Membrane Irregularity Factor (DIF) for the diagnosis and evaluation of conditions such as keratoplasty rejection and failure and Fuchs' dystrophy. These improved indices may be incorporated into optical coherence tomography systems, or any other imaging device capable of capturing high resolution images of the cornea, for more sensitive and specific diagnosis, treatment, and monitoring of certain corneal conditions, in addition to the evaluation of new treatments.

A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from omega choline, in which said omega choline contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases.

The invention relates to artificial tear containing trehalose and the preparation and application method, which pertains to the technical field of pharmaceutical manufacture. The main component of the invention is the trehalose, the basic composition of the artificial tear is the trehalose, simulating mucin protein and conventional ophthalmic pharmaceutical excipients; the weight ratio of the three is that 0.3 to 97 percent trehalose, 0.3 to 97 percent simulating mucin protein and 2 to 98 percent conventional ophthalmic pharmaceutical excipients. The pH and the osmotic pressure of the artificial tear of the invention are equivalent to physiologic tear, the invention contains rich electrolyte ions, the type and the content of the ions are equivalent to the physiologic tear, and the invention can be used in the treatment of dry eye syndrome and the adjuvant treatment of diseases which are caused by other dry eye syndromes. At the same time, the invention can be used as the drug delivery system of various ophthalmic drugs.

The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals.

The invention relates to artificial tears, in particular to artificial tears including carnosine, concretely, the artificial tears including carnosine comprise the following components and contents in percentage by weight: 0.2-5.0 percent of carnosine, an osmotic pressure regulator, a pH regulator and the balance of water, wherein the osmotic pressure regulator makes the mill-osmotic pressure mol concentration ratio of the artificial tears be between 0.9 and 1.1, and the pH regulator makes the pH value of the artificial tears be between 5.0 and 9.0. The artificial tears including carnosine can be used for treating dry eye syndrome, and also has a function of preventing cataract. The invention also relates to a preparation method of the artificial tears.